Crystal forms I and II of tasimelteon. Crystal form I: an X-ray powder diffraction spectrum using CuK radiation and represented by a 2 angle has diffraction peaks at least at 7.20.2, 7.90.2, 10.60.2, 14.40.2, 15.90.2, 17.30.2, 21.00.2, 23.20.2, and 24.40.2. Crystal form II: an X-ray powder diffraction spectrum using CuK radiation and represented by a 2 angle has diffraction peaks at least at 6.80.2, 12.10.2, 12.50.2, 13.10.2, 13.60.2, 13.80.2, 15.80.2, 17.00.2, 18.40.2, 20.80.2, 24.20.2, and 24.40.2. Crystal forms I and II of tasimelteon have advantages of excellent physicochemical property, good stability and solubility, and simple operation for preparation.

The present disclosure provides a process for preparing Bortezomib, intermediates, and crystalline forms thereof.

The present invention provides a crystal of reduced glutathione that is stable, and is easy to process, and a method for producing the crystal. According to the present invention, a crystal of a metal salt of reduced glutathione is produced by suspending an amorphous solid of a metal salt of reduced glutathione in a hydrophobic organic solvent, and adding water to the resulting suspension to precipitate a crystal of a metal salt of reduced glutathione.

The subject-matter of the invention is process for the separation of optical isomers of racemic 3-alk-3-carboxylic acid ethyl esters of formula rac-I with the resolving agent (II) ()-2,3:4,5-di-O-izopropylidene-2-keto-L-gulonic acid (hereinafter: diacetone-L-ketogulonic acid).

Process for making solid methylglycine diacetate (MGDA) alkali metal salt (a), said process comprising the steps of (A) providing a 35 to 60% by weight aqueous solution of said MGDA salt having a temperature in the range of from 50 to 90 C., (B) adding 0.01 to 2% by weight of a particulate solid with a pore volume in the range of from 0.25 to 0.75 cm.sup.3/g, determined by nitrogen adsorption in accordance with 66134:1998-02 (b), the percentage referring to the content of (a), (C) crystallizing (a), (D) removing said crystalline (a) from the mother liquor.

The present invention provides an industrial method production of amorphous posaconazole. The present invention also relates to a method for production of the posaconazole via and novel crystalline forms of posaconazole intermediate. More particularly the present invention relates to novel crystalline forms of posaconazole intermediate and methods for production of novel crystalline forms of posaconazole intermediate represented by the following structural formula III Which is key intermediate in the production of posaconazole. The present invention also provides for the one pot process for the preparation of amorphous posaconazole using novel crystalline forms of benzyl posaconazole.

##STR00001##

A process for preparing (3R)-3-[2-Hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide) comprises reacting 2-hydroxy-2,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R) yl methyl ester and 3-phenoxypropyl bromide, wherein the reaction takes place in a solvent or mixture of solvents selected from the group of amides and/or the group of solvents with a sulfoxide group. Also provided is a crystalline aclidinium bromide characterized by a powder XRPD pattern having peaks at 7.70.2 2, 10.40.2 2, 13.20.2 2, 13.80.2 2, 19.90.2 2, 20.30.2 2, 20.80.2 2, 24.20.2 2, 25.70.2 2, 26.10.2 2, 29.20.2 2, 30.80.2 2. A pharmaceutical composition comprises aclidinium bromide according to the invention and a pharmaceutically acceptable excipient.

Provided are: an economically superior protein crystallization method capable of efficiently finding conditions for crystallization by using a small amount of protein; and a crystallization device used for the method. According to the present invention, a transparent sealed container 1 is filled with a solution of protein, a part of the transparent sealed container 1 being formed of a semipermeable membrane 2 with a molecular weight cut-off that inhibits passage of the protein while allowing passage of a precipitant, and then, a precipitant solution with changed concentration and/or pH of the precipitant is continuously supplied to the semipermeable membrane 2, to crystallize the protein with the precipitant that infiltrates from the semipermeable membrane 2 into the sealed container 1.

Method for the separation of at least one isoprenic constituent from the resin of a plant of guayule and/or of the guayule type comprising the steps of: a) providing a defatted resin of guayule and/or of the guayule type; b) subjecting the defatted resin to partitioning of the liquid-liquid type with solvents that are immiscible in each other thus obtaining an apolar extract containing the isoprenic constituents guayulin A, guayulin B and argentatin B; and a polar extract containing the isoprene constituents argentatin A, argentatin C and argentatin D; and c) separating at least one isoprenic constituent from said polar extract and/or from the apolar extract thus obtained, wherein step c) comprises a step in which the polar extract is subjected to partitioning of the liquid-liquid type with solvents immiscible in each other and/or a step in which the apolar extract is subjected to partitioning of the solid-liquid type.

This disclosure provides a process for preparing 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones, specially provides a method for preparing the compound of Formula I, and the method comprises the step of reacting the compound of Formula II with the compound of Formula A in the presence of a condensation agent, an organic base and an organic solvent by condensation. ##STR00001##